



# SIGACHI LABORATORIES LIMITED

Corporate Office : 411 , Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 4.2.2026

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
205(A), 2nd floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 4<sup>th</sup> February, 2026 - Reg.

Ref: - Disclosure under Regulation 30 & 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Reg.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Wednesday, 4<sup>th</sup> February, 2026 had inter-alia considered transacted and approved the following items of business:

- 1, Approved the Un-audited Financial Results along with the segment results for the quarter and nine months ended 31<sup>st</sup> December, 2025.
2. Taken on record the Limited Review Report received from the statutory auditors of the company for the quarter and nine months ended 31<sup>st</sup> December, 2025.

We wish to inform that the company has not issued any Non-Convertible Debt Securities, Non-Convertible Redeemable Preference Shares (NCRPS) and Commercial Papers or any other instruments and as such the SEBI circular no. SEBI/HO/DDHS/DDHS/CIR/P/2020/231 dated November 13, 2020 is not applicable to the company.



# SIGACHI LABORATORIES LIMITED

Corporate Office: 411 , Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

We herewith enclose the following:

- A. Un-Audited financial Results along with the segment results, for the quarter and nine months ended 31<sup>st</sup> December, 2025.
- B. Review Report issued by the Statutory Auditors for the quarter and nine months ended 31<sup>st</sup> December, 2025.
- C. Letter confirming Non applicability of Regulations 51, 52 and 54 of SEBI (LODR), Regulations, 2015 for the Quarter ended 31.12.2025.
- D. Statement of Deviation under regulation 32 of the SEBI (LODR) Regulations, 2015.

Kindly take the above on your records.

Thanking you,

Yours faithfully,  
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)  
Company Secretary

The meeting Commenced at 4:00 PM

The Meeting Concluded at 8:00 PM

**SIGACHI LABORATORIES LIMITED**

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For the Quarter and Nine Months ended 31st December, 2025

(Rs. in Lakhs)

Sl.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	91.88	30.40	48.28	250.04	248.36	312.23
2	Other income	14.98	14.60	14.68	51.29	48.91	65.95
3	Total Income (1+2)	106.86	45.00	62.96	301.33	297.27	378.18
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Impairment on Advances	-	-	-	-	-	75.00
	d) Fair Value Loss	-	-	60.28	-	-	68.77
	e) Employee benefits expense	11.62	11.94	11.12	34.07	31.53	42.90
	f) Finance costs	0.07	-	-	0.07	-	-
	g) Depreciation and amortization expense	8.37	5.78	5.81	19.93	17.39	23.17
	h) Other expenses	5.16	2.99	3.48	12.02	10.65	16.12
	Total Expenses	25.22	20.71	80.69	66.09	59.57	225.96
5	Profit/(Loss) before exceptional items and tax (3-4)	81.64	24.29	(17.73)	235.24	237.70	152.22
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(Loss) before tax (5-6)	81.64	24.29	(17.73)	235.24	237.70	152.22
8	Tax expense						
	(a) Current tax	13.24	12.32	11.15	36.17	31.33	45.61
	(b) Deferred tax	6.86	(6.15)	(1.84)	10.41	(3.00)	(12.49)
	Total Tax Expense	20.10	6.17	9.31	46.58	28.33	33.12
9	Profit/(Loss) for the Period (7-8)	61.54	18.12	(27.04)	188.66	209.37	119.10
10	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or (loss)	147.66	(35.48)	(69.91)	318.34	419.69	247.67
	(b) Remeasurement gains/(losses) on defined benefit plans	-	-	-	-	-	0.57
	(c) Tax on Items that will not be reclassified to profit or (loss)	27.77	11.73	(9.10)	45.52	(60.01)	(35.52)
	(d) Items that will be reclassified to profit or (loss)	-	-	-	-	-	-
	(e) Items that may be reclassified subsequently to profit or (loss)	-	-	-	-	-	-
	Total other Comprehensive income for the period, net of tax	119.89	(23.75)	(79.01)	272.82	359.68	212.72
	Total Comprehensive income (9+10)	181.43	(5.63)	(106.05)	461.48	569.05	331.82
11	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.31	675.31	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	-	-	3,201.66
13	Earnings per equity share (of Rs.10/- each) (not annualized (in Rs.))						
	(1) Basic	0.91	0.27	(0.40)	2.79	3.10	1.76
	(2) Diluted	0.91	0.27	(0.40)	2.79	3.10	1.76

Segment wise Revenue, Results and Capital Employed for the Quarter and Nine Months Ended 31st December, 2025

(Rs. in Lakhs)

Sl.No	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	39.00	39.00	35.00	103.00	92.50	140.50
	b) Investments	67.86	6.00	27.96	198.33	204.77	237.68
	<b>Total</b>	<b>106.86</b>	<b>45.00</b>	<b>62.96</b>	<b>301.33</b>	<b>297.27</b>	<b>378.18</b>
	Less: Inter Segment Revenue	-	-	-	-	-	-
	<b>Net Sales/Income from Operations</b>	<b>106.86</b>	<b>45.00</b>	<b>62.96</b>	<b>301.33</b>	<b>297.27</b>	<b>378.18</b>
2	Segment Results Profit/(Loss) before tax and finance costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	30.45	33.04	28.94	82.17	74.32	115.42
	b) Investments	67.86	6.00	(32.32)	198.33	204.77	168.91
	<b>Total</b>	<b>98.31</b>	<b>39.04</b>	<b>(3.38)</b>	<b>280.50</b>	<b>279.09</b>	<b>284.33</b>
	Less: (i) Finance Costs	0.07	-	-	0.07	-	-
	(ii) Other Un-allocable Expenditure net off	16.60	14.75	14.35	45.19	41.39	132.11
	(iii) Un-allocable income	-	-	-	-	-	-
	<b>Total Profit/(loss) Before Tax</b>	<b>81.64</b>	<b>24.29</b>	<b>(17.73)</b>	<b>235.24</b>	<b>237.70</b>	<b>152.22</b>
3	Capital Employed						
	Segment Assets						
	a) Bulk Drugs and Intermediates (leased)	873.31	922.07	980.61	873.31	980.61	949.70
	b) Investments	3,752.96	3,479.55	3,379.16	3,752.96	3,379.16	3,141.63
	<b>Total (A)</b>	<b>4,626.27</b>	<b>4,401.62</b>	<b>4,359.77</b>	<b>4,626.27</b>	<b>4,359.77</b>	<b>4,091.33</b>
4	Segment Liabilities						
	a) Bulk Drugs and Intermediates (leased)	172.58	164.40	113.25	172.58	113.25	116.12
	b) Investments	59.49	24.45	76.57	59.49	76.57	42.49
	<b>Total (B)</b>	<b>232.07</b>	<b>188.85</b>	<b>189.82</b>	<b>232.07</b>	<b>189.82</b>	<b>158.61</b>
	<b>Total (A-B)</b>	<b>4,394.20</b>	<b>4,212.77</b>	<b>4,169.95</b>	<b>4,394.20</b>	<b>4,169.95</b>	<b>3,932.72</b>

Notes :

- The above unaudited Financial results as reviewed and recommended by the Audit Committee are considered and approved by the Board of Directors at their respective meetings held on 04th February, 2026.
- These financial results of the company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- These Financial results have been subjected to limited review by the Statutory Auditors'.
- The Company's 'Bulk Drugs and Intermediates (Leased) Segment' consists of factories leased out under a long-term lease agreement approved by the shareholders. For the quarter ended 31-12-2025, 100% of the Lease rents and 100% of the company's trade receivables are derived from a single non-related party - Lessee. The Management has assessed the credit risk and considers the amount fully recoverable.
- These Financial Results are available on the Stock Exchange website at (www.msei.in) and also on the company's website at (www.slilab.com).

for SIGACHI LABORATORIES LIMITED

(T.R.Sekhar)  
Executive Director  
DIN:02943146

Place : Hyderabad  
Date : 04.02.2026

**Independent Auditor's Review Report on the Quarter and nine months ended 31<sup>st</sup> December, 2025  
Unaudited Financial Results of the Company pursuant to the Regulations 33 of the SEBI (Listing  
Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To The Board of Directors of **SIGACHI LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **SIGACHI LABORATORIES LIMITED** ("the Company") for the quarter and nine months ended 31<sup>st</sup> December 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1/44/2019 "Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**NSVR & ASSOCIATES LLP**



**NSVR & ASSOCIATES LLP.,**  
CHARTERED ACCOUNTANTS

Our conclusion on the statement in respect of these matters is not modified with respect to the financial results and other financial information certified by the management.

**For M/s. NSVR & ASSOCIATES LLP**  
Chartered accountants  
FRN: 008801S/S200060

  


**V Gangadhara Rao N**  
Partner  
Membership No: 219486  
UDIN: 26219486BS2QVQ5792

Place: Hyderabad  
Date: 04-02-2026

---

**NSVR & ASSOCIATES LLP**

House No.1-89/1/42, 3rd Floor, Plot No. 41 & 43, Sri Ram Nagar Colony, Kavuri Hills, Guttala Begumpet,  
Madhapur, Hyderabad, Telangana - 500081. | Ph: 040 - 23391164, E-mail: info@nsvr.in



# SIGACHI LABORATORIES LIMITED

Corporate Office: 4th, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

4.2.2026

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
205(A), 2nd floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West), Mumbai - 400070

Dear Sir,

Sub: Sigachi Laboratories Limited - Intimation of Non Applicability of Regulations  
51, 52 and 54 of SEBI (LODR), Regulations, 2015 for the Quarter ended 31.12.2025 -  
Reg.

\*\*\*

With respect to above cited subject, we would like to inform your good office that the following regulations of the SEBI (LODR) Regulations, 2015, as amended, are not applicable to our company:

S No.	Particulars	Regulation	Applicability
1.	Price Sensitive Information/ disclosure of event/ Information	Reg. 51(1) & 51 (2) SEBI (LODR) Regulations, 2015	Debt
2.	Submission of Financial Results	Reg. 52(1) SEBI (LODR) Regulations, 2015	Debt
3.	Submission of line items along with Financial Results	Reg. 52(4) & 52 (6) SEBI (LODR) Regulations, 2015	Debt
4.	Asset Cover	Reg. 54(2) & 54 (3) SEBI (LODR) Regulations, 2015	Debt
5.	Utilization of issue proceeds/ material deviation in the use of proceeds	Reg. 52(7) & 52(7A) SEBI (LODR) Regulations, 2015	Debt

We hereby certify that the Company has not issued any non-convertible securities or instruments of similar nature at any time for the quarter ended 31.12.2025 and therefore the disclosures required as per aforementioned regulations are not applicable to the company.

We request you to take the above in your records.

Thanking you,

Yours Faithfully  
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)  
Company Secretary



# SIGACHI LABORATORIES LIMITED

Corporate Office: 411 , Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 4.2.2026

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
205(A), 2nd floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Non-Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 - Reg.

\*\*\*

Pursuant to the Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the company had made its public offer (Initial Public Offer IPO) nearly about 28 years back and the Company has fully utilized the proceeds of the IPO for the purpose for which the funds were raised. The company has not raised any fresh issue after Initial public issue - through public issue, rights issue, preferential issue, QIP, etc., Hence, the Statement of deviation(s) or variation(s) is not applicable to the Company

We request you to kindly take note of this information on your record and acknowledge.

Thanking you,

Yours faithfully,  
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)  
Company Secretary